When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

October 13, 2020

STAT News

Related news

In the news

December 14, 2021

Digital Therapeutics Shaping the Future of Care

Managed Healthcare Executive

In the news

November 22, 2021

A legacy of leadership: Chris Bent

University of Minnesota